NCT06870487 - A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 8, 2025

Primary Completion Date

February 27, 2026

Study Completion Date

February 27, 2026

Conditions

Peripheral T Cell LymphomaDiffuse Large B-cell LymphomaClassical Hodgkin LymphomaHead and Neck Squamous Cell CarcinomaMelanomaNon-Small Cell Lung Cancer

Interventions

DRUG

PF-08046032

PF-08046032 will be administered intravenously (IV) infusion.

DRUG

Sasanlimab

Sasanlimab will be administered as subcutaneous (SC) injection.

Trial Locations (4)

28040

Hospital Universitario Fundación Jiménez Díaz, Madrid

78229

NEXT Oncology, San Antonio

98109

Fred Hutchinson Cancer Center., Seattle

98195

University of Washington Medical Center- Montlake, Seattle